Annotation Detail
Information
- Associated Genes
- FGF19
- Associated Variants
-
FGF19 EXPRESSION
FGF19 EXPRESSION - Associated Disease
- hepatocellular carcinoma
- Source Database
- CIViC Evidence
- Description
- In a phase 1 trial, patients with hepatocellular carcinoma were treated with selective FGFR4 inhibitor, fisogatinib (BLU-554). For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily. FGF19 expression was evaluated by immunohistochemistry. Across doses, the overall response rate was 17% (11/66) in FGF19 positive patients and 0% (0/32) in FGF19 negative patients.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7636
- Gene URL
- https://civic.genome.wustl.edu/links/genes/7909
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2827
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Hepatocellular Carcinoma
- Evidence Direction
- Supports
- Drug
- FGFR4 Inhibitor BLU-554
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 31575541
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| FGFR4 Inhibitor BLU-554 | Sensitivity | true |